(3R)-cyclopentylmethyl-4-[2-(furan-2-carbonyl)-tetrahydropyridazin-1-yl]-N-hydroxy-4-oxo-butyramide | 706778-79-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: (3R)-cyclopentylmethyl-4-[2-(furan-2-carbonyl)-tetrahydropyridazin-1-yl]-N-hydroxy-4-oxo-butyramide
• 英文别名: (3R)-3-(cyclopentylmethyl)-4-[2-(furan-2-carbonyl)diazinan-1-yl]-N-hydroxy-4-oxobutanamide
• CAS: 706778-79-2
• 化学式: C₁₉H₂₇N₃O₅
• 分子量: 377.44
• InChiKey: SUPYARUUYLLAMF-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (3R)-cyclopentylmethyl-N-(1-isobutoxyethoxy)-4-oxo-(tetrahydropyridazin-1-yl)-butyramide 在 盐酸 、 水 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 (3R)-cyclopentylmethyl-4-[2-(furan-2-carbonyl)-tetrahydropyridazin-1-yl]-N-hydroxy-4-oxo-butyramide
  参考文献：
  名称：

  Peptidomimetic inhibitors of bacterial peptide deformylase

  摘要：

  A series of N-formyl hydroxylamine peptide deformylase inhibitors containing a cyclic azaamino acid moiety between the P1' and P3' substituents are presented. Selected compounds display antibacterial activity against pathogens associated with respiratory tract infections with representative compounds showing excellent MICs against Haemophilus influenzae. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.132

文献信息

• [EN] ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS
  申请人：VERNALIS OXFORD LTD

  公开号：WO2004050638A1

  公开（公告）日：2004-06-17

  Compounds of formula (I) have antibacterial activity; wherein Q represents a radical of formula -N(OH)CH(=O) or formula -C(=O)NH(OH); Y represents -C(=O)-, -C(=S)-, -S(=O)-, or -SO2-; R1 represents hydrogen, Cl-C6 alkyl or Cl-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of formula -N(OH)CH(=O), a hydroxy, Cl-C6 alkoxy, C1-C6 alkenyloxy, halogen, amino, Cl-C6 alkylamino, or di-( Cl-C6 alkyl)amino group; R2 represents a substituted or unsubstituted Cl-C6 alkyl, Cl-C3 alkyl-O-C1-C3 alkyl, C1-C3 alkyl-S-Cl-C3 alkyl, cycloalkyl(Cl-C3 alkyl)-, aryl(C1-C3 alkyl)-, heterocyclyl(Cl-C3 alkyl)-, or R1R2N-C1-C3 alkyl group wherein R1 represents hydrogen or C1-C3 alkyl and R2 represents Cl-C3 alkyl, or R1R2N- represents a cyclic amino group; R3 and R4 taken together with the nitrogen atoms to which they are respectively attached form a saturated heterocyclic ring of from 4 to 7 ring atoms, which may be fused to a second carbocyclic or heterocyclic ring, either of which rings may optionally be substituted; and A represents a primary, secondary or tertiary amino group or a group -R5, -OR5, wherein R5 is a substituted or unsubstituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclyl, Cl-C3 alkyl-O-C1-C3 alkyl, Cl-C3 alkyl-S-Cl-C3 alkyl, cycloalkyl(Cl-C3 alkyl)-, heterocyclic(Cl-C3 alkyl, aryl(Cl-C3 alkyl)-or R1R2N-C1-C3 alkyl group wherein R1 represents hydrogen or Cl-C3 alkyl and R2 represents Cl-C3 alkyl, or R1R2N- represents a cyclic amino group.

  式(I)的化合物具有抗菌活性；其中Q代表式-N(OH)CH(=O)的基团或式-C(=O)NH(OH)的基团；Y代表-C(=O)-、-C(=S)-、-S(=O)-或-SO2-；R1代表氢、Cl-C6烷基或一个或多个卤素原子取代的Cl-C6烷基，或者除非Q是式-N(OH)CH(=O)的基团，否则为羟基、Cl-C6烷氧基、C1-C6烯氧基、卤素、氨基、Cl-C6烷基氨基或双-(Cl-C6烷基)氨基；R2代表取代或未取代的Cl-C6烷基、Cl-C3烷基-O-C1-C3烷基、C1-C3烷基-S-Cl-C3烷基、环烷基(Cl-C3烷基)-、芳基(C1-C3烷基)-、杂环烷基(Cl-C3烷基)-，或R1R2N-C1-C3烷基基团，其中R1代表氢或C1-C3烷基，R2代表Cl-C3烷基，或R1R2N-代表一个环状氨基基团；R3和R4与它们分别连接的氮原子一起形成由4至7个环原子组成的饱和杂环环，可以与第二个碳环或杂环环融合，其中任一环均可选择性地被取代；A代表主要的、次要的或三级胺基团或一个基团-R5、-OR5，其中R5是取代或未取代的C1-C6烷基、C2-C6烯基、C2-C6炔基、环烷基、芳基、杂环烷基、Cl-C3烷基-O-C1-C3烷基、Cl-C3烷基-S-Cl-C3烷基、环烷基(Cl-C3烷基)-、杂环烷基(Cl-C3烷基)、芳基(Cl-C3烷基)-或R1R2N-C1-C3烷基基团，其中R1代表氢或Cl-C3烷基，R2代表Cl-C3烷基，或R1R2N-代表一个环状氨基基团。
• Peptidomimetic inhibitors of bacterial peptide deformylase
  作者：Stephen P. East、Andrew Ayscough、Ian Toogood-Johnson、Steven Taylor、Wayne Thomas

  DOI：10.1016/j.bmcl.2011.04.132

  日期：2011.7

  A series of N-formyl hydroxylamine peptide deformylase inhibitors containing a cyclic azaamino acid moiety between the P1' and P3' substituents are presented. Selected compounds display antibacterial activity against pathogens associated with respiratory tract infections with representative compounds showing excellent MICs against Haemophilus influenzae. (C) 2011 Elsevier Ltd. All rights reserved.